Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life ...

Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of ...

Chief Financial Officer Julie Brown noted, "Core operating margin improved to 29.2%, up 130 basis points year-on-year," driven by specialty medicines and supply chain efficiencies. GSK expects ...

Developers celebrate gains for advances with radiopharmaceuticals while regulators and isotope suppliers work to keep up.

The deal was signed with the Energize programme, a renewable energy purchasing vehicle for pharmeceutical companies.

GSK'227 targets B7-H3 ... benefiting from the positive mix from specialty medicines and the supply chain efficiencies. Despite incorporating £150 million charge to drive future supply chain ...

The molecule is also being tested in over 100 vaccine clinical trials. Rising QS-21 demand from the pharmaceutical industry ...

X-Elio will supply 245GWh of clean energy annually to four pharmaceutical companies through its Lorca Solar project.

Jeff Bezos also spoke at the forum, which was held just 50 miles west of Cape Canaveral, about his space company Blue Origin.

Q4 2024 Management View CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit ...

GSK has pledged to 100% use of renewable across the company by 2025, and an 80% reduction in carbon emissions by 2030 en route to net zero across all its supply chain – including purchased goods ...